Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2007

Open Access 01-12-2007 | Research

Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial

Authors: Paul Glasziou, Jan Alexander, Elaine Beller, Philip Clarke, the ADVANCE Collaborative Group

Published in: Health and Quality of Life Outcomes | Issue 1/2007

Login to get access

Abstract

Background

Diabetes has a high burden of illness both in life years lost and in disability through related co-morbidities. Accurate assessment of the non-mortality burden requires appropriate health-related quality of life and summary utility measures of which there are several contenders. The study aimed to measure the impact of diabetes on various health-related quality of life domains, and compare several summary utility measures.

Methods

In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) study, 978 Australian patients with Type 2 diabetes completed two health-related quality of life questionnaires at baseline: the EQ-5D and the SF-36v2, from which nine summary utility measures were calculated, and compared. The algorithms were grouped into four classes: (i) based on the EQ-5D; (ii) using fewer items than those in the SF-12 (iii) using the items in the SF-12; and (iv) using all items of the SF-36.

Results

Overall health-related quality of life of the subjects was good (mean utility ranged from 0.68 (±0.08) to 0.85(±0.14) over the nine utility measures) and comparable to patients without diabetes. Summary indices were well correlated with each other (r = 0.76 to 0.99), and showed lower health-related quality of life in patients with major diabetes-related events such as stroke or myocardial infarction. Despite the smaller number of items used in the scoring of the EQ-5D, it generally performed at least as well as SF-36 based methods. However, all utility measures had some limitation such as limited range or ceiling effects.

Conclusion

The summary utility measures showed good agreement, and showed good discrimination between major and minor health state changes. However, EQ-5D based measures performed as well and are generally simpler to use.
Appendix
Available only for authorised users
Literature
1.
go back to reference EuroQol Group: EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9CrossRef EuroQol Group: EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9CrossRef
2.
go back to reference Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36) conceptual framework and item selection. Med Care 1992, 30: 473–483. 10.1097/00005650-199206000-00002PubMedCrossRef Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36) conceptual framework and item selection. Med Care 1992, 30: 473–483. 10.1097/00005650-199206000-00002PubMedCrossRef
3.
go back to reference Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med-Decis-Making 2002, 22: 340–349. 10.1177/027298902400448902PubMedCrossRef Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med-Decis-Making 2002, 22: 340–349. 10.1177/027298902400448902PubMedCrossRef
4.
go back to reference The FIELD study investigators: Effects of long-term fenonibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005, 366: 1849–1861. 10.1016/S0140-6736(05)67667-2CrossRef The FIELD study investigators: Effects of long-term fenonibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005, 366: 1849–1861. 10.1016/S0140-6736(05)67667-2CrossRef
5.
go back to reference ADVANCE Management Committee: Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation. Diabetologia 2001, 44: 1118–1120. 10.1007/s001250100612CrossRef ADVANCE Management Committee: Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation. Diabetologia 2001, 44: 1118–1120. 10.1007/s001250100612CrossRef
6.
go back to reference Clarke P, Simon J, Cull CA, Holman RR: Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care 2006, 29: 1506–1511. 10.2337/dc05-2150PubMedCrossRef Clarke P, Simon J, Cull CA, Holman RR: Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care 2006, 29: 1506–1511. 10.2337/dc05-2150PubMedCrossRef
7.
go back to reference Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI: A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002, 25: 1737–1743. 10.2337/diacare.25.10.1737PubMedCrossRef Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI: A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002, 25: 1737–1743. 10.2337/diacare.25.10.1737PubMedCrossRef
8.
go back to reference Dolan P: Modeling Valuations for EuroQol Health States. Med Care 1997, 35: 1095–1108. 10.1097/00005650-199711000-00002PubMedCrossRef Dolan P: Modeling Valuations for EuroQol Health States. Med Care 1997, 35: 1095–1108. 10.1097/00005650-199711000-00002PubMedCrossRef
9.
go back to reference Shaw JW, Johnson JA, Coons SJ: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005, 43: 203–220. 10.1097/00005650-200503000-00003PubMedCrossRef Shaw JW, Johnson JA, Coons SJ: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005, 43: 203–220. 10.1097/00005650-200503000-00003PubMedCrossRef
10.
go back to reference Lundberg L, Johannesson M, Isacson DGL, Borgquist L: The Relationship between Health-state Utilities and the SF-12 in a General Population. Med Decis Making 1999, 19: 128–140. 10.1177/0272989X9901900203PubMedCrossRef Lundberg L, Johannesson M, Isacson DGL, Borgquist L: The Relationship between Health-state Utilities and the SF-12 in a General Population. Med Decis Making 1999, 19: 128–140. 10.1177/0272989X9901900203PubMedCrossRef
11.
go back to reference ADVANCE Collaborative Group: ADVANCE – Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 2005, 22: 882–888. 10.1111/j.1464-5491.2005.01596.xCrossRef ADVANCE Collaborative Group: ADVANCE – Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 2005, 22: 882–888. 10.1111/j.1464-5491.2005.01596.xCrossRef
12.
go back to reference Brazier J, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851–859. 10.1097/01.mlr.0000135827.18610.0dPubMedCrossRef Brazier J, Roberts J: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851–859. 10.1097/01.mlr.0000135827.18610.0dPubMedCrossRef
13.
go back to reference Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21: 271–292. 10.1016/S0167-6296(01)00130-8PubMedCrossRef Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21: 271–292. 10.1016/S0167-6296(01)00130-8PubMedCrossRef
14.
go back to reference Lawrence W, Fleishman J: Predicting EuroQol EQ-5D preference scores from the SF-12 health survey in a nationally representative sample. Med Decis Making 2004, 24: 160–169. 10.1177/0272989X04264015PubMedCrossRef Lawrence W, Fleishman J: Predicting EuroQol EQ-5D preference scores from the SF-12 health survey in a nationally representative sample. Med Decis Making 2004, 24: 160–169. 10.1177/0272989X04264015PubMedCrossRef
15.
go back to reference Franks P, Lubetkin E, Gold M, Tancredi D, Jia H: Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making 2004, 24: 247–254. 10.1177/0272989X04265477PubMedCrossRef Franks P, Lubetkin E, Gold M, Tancredi D, Jia H: Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making 2004, 24: 247–254. 10.1177/0272989X04265477PubMedCrossRef
16.
go back to reference Franks P, Lubetkin E, Gold M, Tancredi D: Mapping the SF-12 to preference-based instruments – convergent validity in a low-income, minority population. Med Care 2003, 41: 1277–1283. 10.1097/01.MLR.0000093480.58308.D8PubMedCrossRef Franks P, Lubetkin E, Gold M, Tancredi D: Mapping the SF-12 to preference-based instruments – convergent validity in a low-income, minority population. Med Care 2003, 41: 1277–1283. 10.1097/01.MLR.0000093480.58308.D8PubMedCrossRef
17.
go back to reference Fryback D, Lawrence W, Martin P, Klein R, Klein B: Predicting quality of well-being scores from the SF-36. Med Decis Making 1997, 17: 1–9. 10.1177/0272989X9701700101PubMedCrossRef Fryback D, Lawrence W, Martin P, Klein R, Klein B: Predicting quality of well-being scores from the SF-36. Med Decis Making 1997, 17: 1–9. 10.1177/0272989X9701700101PubMedCrossRef
18.
go back to reference Huang ES, Shook M, Jin L, Chin MH, Meltzer DO: The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care 2006, 29: 259–264. 10.2337/diacare.29.02.06.dc05-1443PubMedCentralPubMedCrossRef Huang ES, Shook M, Jin L, Chin MH, Meltzer DO: The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care 2006, 29: 259–264. 10.2337/diacare.29.02.06.dc05-1443PubMedCentralPubMedCrossRef
19.
go back to reference Longworth L, Bryan S: An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003, 12: 1061–1067. 10.1002/hec.787PubMedCrossRef Longworth L, Bryan S: An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003, 12: 1061–1067. 10.1002/hec.787PubMedCrossRef
20.
go back to reference Conner-Spady B, Suarez-Almazor ME: Variation in the Estimation of Quality-adjusted Life-years by Different Preference-based Instruments. Medical Care 2003, 41: 791–801. 10.1097/00005650-200307000-00003PubMedCrossRef Conner-Spady B, Suarez-Almazor ME: Variation in the Estimation of Quality-adjusted Life-years by Different Preference-based Instruments. Medical Care 2003, 41: 791–801. 10.1097/00005650-200307000-00003PubMedCrossRef
21.
go back to reference Ware JE, Snow KK, Kosinski M, Gandek B: SF-36® Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute; 1993. Ware JE, Snow KK, Kosinski M, Gandek B: SF-36® Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute; 1993.
22.
go back to reference Weinberger M, Samsa GP, Hanlon JT, Schmader K, Doyle ME, Cowper PA, Uttech KM, Cohen HJ, Feussner JR: An evaluation of a brief health status measure in elderly veterans. J Am Geriatr Soc 1991, 39: 691–694.PubMedCrossRef Weinberger M, Samsa GP, Hanlon JT, Schmader K, Doyle ME, Cowper PA, Uttech KM, Cohen HJ, Feussner JR: An evaluation of a brief health status measure in elderly veterans. J Am Geriatr Soc 1991, 39: 691–694.PubMedCrossRef
23.
go back to reference Gerard K, Nicholson T, Mullee M, Mehta R, Roderick P: EQ-5D versus SF-6D in an Older, Chronically Ill Patient Group. Applied Health Economics & Health Policy 2004, 3: 91–102. 10.2165/00148365-200403020-00005CrossRef Gerard K, Nicholson T, Mullee M, Mehta R, Roderick P: EQ-5D versus SF-6D in an Older, Chronically Ill Patient Group. Applied Health Economics & Health Policy 2004, 3: 91–102. 10.2165/00148365-200403020-00005CrossRef
24.
go back to reference Bagust A, Beale S: Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005, 14: 217–230. 10.1002/hec.910PubMedCrossRef Bagust A, Beale S: Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005, 14: 217–230. 10.1002/hec.910PubMedCrossRef
Metadata
Title
Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial
Authors
Paul Glasziou
Jan Alexander
Elaine Beller
Philip Clarke
the ADVANCE Collaborative Group
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2007
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-5-21

Other articles of this Issue 1/2007

Health and Quality of Life Outcomes 1/2007 Go to the issue